Variant genotypes of FcγRIIIA influence the development of Kaposi's sarcoma in HIV-infected men

Blood

Volumn 95, Issue 7, 2000, Pages 2386-2390

  Lehrnbecher, Thomas ^b   Foster, Charles B ^b   Zhu, Shaoxian ^b   Venzon, David ^b   Steinberg, Seth M ^b   Wyvill, Kathleen ^b   Metcalf, Julia A ^b   Cohen, Sandra S ^b   Kovacs, Joseph ^b   Yarchoan, Robert ^b   Blauvelt, Andrew ^b   Chanock, Stephen J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN G; VIRUS ANTIBODY;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA POLYMORPHISM; GENOTYPE; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREGULATION; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEPTOR AFFINITY; VIRUS INFECTION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; POLYMERASE CHAIN REACTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIBODIES, VIRAL; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HERPESVIRUS 8, HUMAN; HUMANS; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RECEPTORS, IGG; SARCOMA, KAPOSI;

EID: 0034164065     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.7.2386.007k04_2386_2390     Document Type: Article

References (61)

1. Safai B, Johnson KG, Myskowski PL, et al. The natural history of Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med. 1985;103:744-750.
2. Haverkos HW, Drotman DP. Prevalence of Kaposi's sarcoma among patients with AIDS. N Engl J Med. 1985;312:1518.
3. Geddes M, Franceschi S, Balzi D, Arniani S, Gafa L, Zanetti R. Birthplace and classic Kaposi's sarcoma in Italy: Associazione Italiana Registri Tumori. J Natl Cancer Inst. 1995;87:1015-1017.
4. Penn I. Kaposi's sarcoma in organ transplant recipients: report of 20 cases. Transplantation. 1979;27:8-11.
5. Slavin G, Cameron HM, Singh H. Kaposi's sarcoma in mainland Tanzania: a report of 117 cases. Br J Cancer. 1969;23:349-357.
6. Taylor JF. Smith PG, Bull D, Pike MC. Kaposi's sarcoma in Uganda: geographic and ethnic distribution. Br J Cancer. 1972;26:483-497.
7. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994;266:1865-1869.
8. Ambroziak JA, Blackbourn DJ, Herndier BG, et al. Herpes-like sequences in HIV-infected and uninfected Kaposi's sarcoma patients. Science. 1995;268:582-583.
9. Boshoff C, Schulz TF, Kennedy MM, et al. Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat Med. 1995;1: 1274-1278.
10. Schalling M, Ekman M, Kaaya EE, Linde A, Biberfeld P. A role for a new herpesvirus (KSHV) in different forms of Kaposi's sarcoma. Nat Med. 1995; 1:707-708.
11. Brooks JJ. Kaposi's sarcoma: a reversible hyperplasia. Lancet. 1986;2:1309-1311.
12. Levy JA, Ziegler JL. Acquired immunodeficiency syndrome is an opportunistic infection and Kaposi's sarcoma results from secondary immune stimulation. Lancet. 1983;2:78-81.
13. Rabkin CS, Janz S, Lash A, et al. Monoclonal origin of multicentric Kaposi's sarcoma lesions. N Engl J Med. 1997;336:988-993.
14. Caruso A, Canaris AD, Licenziati S, et al. CD4+ and CD8+ lymphocytes of patients with AIDS synthesize increased amounts of interferon-gamma. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10:462-470.
15. Capobianchi MR, Ameglio F, Fei PC, et al. Coordinate induction of interferon alpha and gamma by recombinant HIV-1 glycoprotein 120. AIDS Res Hum Retroviruses. 1993;9:957-962.
16. Ensoli B, Salahuddin SZ, Gallo RC. AIDS-associated Kaposi's sarcoma: a molecular model for its pathogenesis. Cancer Cells. 1989;1:93-96.
17. Nakamura S, Salahuddin SZ, Biberfeld P, et al. Kaposi's sarcoma cells: long-term culture with growth factor from retrovirus-infected CD4+ T cells. Science. 1988;242:426-430.
18. Ensoli B, Gendelman R, Markham P, et al. Synergy between basic fibroblast growth factor and HIV-1 tat protein in induction of Kaposi's sarcoma. Nature. 1994;371:674-680.
19. Sirianni MC. Vincenzi L, Fiorelli V, et al. Gamma-interferon production in peripheral blood mononuclear cells and tumor infiltrating lymphocytes from Kaposi's sarcoma patients: correlation with the presence of human herpesvirus-8 in peripheral blood mononuclear cells and lesional macrophages. Blood. 1998;91:968-976.
20. van de Winkel J, Capel P. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today. 1993;14:215-221.
21. Nagarajan S, Chesla S, Cobern L, Anderson P, Zhu C, Selvaraj P. Ligand binding and phagocytosis by CD16 (Fc gamma receptor III) isoforms. J Biol Chem. 1995;270:26,762-25,770.
22. Tax W, Tamboer W, Jacobs C, Frenken L, Koene R. Role of polymorphic Fc receptor Fc gamma RIIa in cytokine release and adverse effects of murine IgG1 anti-CD3/T cell receptor antibody (WT31). Transplantation. 1997;63:106-112.
23. Peltz OA, Grundy HO, Lebo RV, Yssel H, Barsh GS, Moore KW. Human Fc gamma RIII: cloning, expression, and identification of the chromosomal locus of two Fc receptors for IgG. Proc Natl Acad Sci U S A. 1989;86:1013-1017.
24. Su Y, Brooks DG, Li L, et al. Myelin protein zero gene mutated in Charcot-Marie-tooth type 1B patients. Proc Natl Acad Sci U S A. 1993;90:10,856-10,860.
25. Parren PW, Warmerdam PA, Boeije LC, et al. On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J Clin Invest. 1992;90:1537-1546.
26. Warmerdam PA, van de Winkel JG, Gosselin EJ, Capel PJ. Molecular basis for a polymorphism of human Fc gamma receptor II (CD32). J Exp Med. 1990;172:19-25.
27. Warmerdam PA, van de Winkel JG, Vlug A, Westerdaal NA, Capel PJ. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol. 1991;147:1338-1343.
28. Wu J, Edberg J, Redecha P, et al. A novel polymorphism of Fc gamma RIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest. 1997;100:1059-1070.
29. Koene H, Kleijer M, Algra J, Roos D, von dem Borne A, de Haas M. Fc gamma RIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gamma RIIIa, independently of the Fc gamma RIIIa-48L/R/H phenotype. Blood. 1997;90:1109-1114.
30. Ory PA, Clark MR, Kwoh EE, Clarkson SB, Goldstein IM. Sequences of complementary DNAs that encode the NA1 and NA2 forms of Fc receptor III on human neutrophils. J Clin Invest. 1989; 84:1688-1691.
31. Ory PA, Goldstein IM, Kwoh EE, Clarkson SB. Characterization of polymorphic forms of Fc receptor III on human neutrophils. J Clin Invest. 1989;83:1676-1681.
32. Lehrnbecher T, Foster CB, Zhu S, et al. Variant genotypes of the low affinity Fc gamma receptors in two control populations and a review of low affinity Fc gamma receptor polymorphisms in control and disease populations. Blood. 1999;94: 4220-4232.
33. Foster CB, Lehrnbecher T, Mol F, et al. Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. J Clin Invest. 1998;102: 2146-2155.
34. Manger K, Repp R, Spriewald BM, et al. Fc-gamma receptor Ma polymorphism in Caucasian patients with systemic lupus erythematosus: association with clinical symptoms. Arthritis Rheum. 1998;41:1181-1189.
35. Norris CF, Surrey S, Bunin GR, Schwartz E, Buchanan GR, McKenzie SE. Relationship between Fc receptor IIA polymorphism and infection in children with sickle cell disease. J Pediatr. 1996;128:813-819.
36. Abadi J, Zhon Z, Dobroszycki J, Pirofski L. Fc gamma RIIa polymorphism in human immunodeficiency virus-infected children with invasive pneumococcal disease. Pediatr Res. 1997;42: 259-262.
37. Koene HR, von dem Borne AEGK, Roos D, de Haas M. Polymorphisms of Fc gamma RIIIa on NK cells and macrophages. In: van de Winkel JGJ, Hogarth PM, eds. The Immunoglobulin Receptors and Their Physiological and Pathological Roles in Immunity. Kluwer Academic Publisher; 1998:135-140.
38. Winkler C, Modi W, Smith MW, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science. 1998;279:389-393.
39. Martin MP, Dean M, Smith MW. et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science. 1998;282:1907-1911.
40. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene: Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science. 1996;273:1856-1862.
41. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Murphy PM. CCR5 promoter polymorphism and HIV-1 disease progression: Multicenter AIDS Cohort Study (MACS). Lancet. 1998;352:866-870.
42. Zimmerman PA, Buckler-White A, Alkhatib G, et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med. 1997;3:23-36.
43. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression: Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science. 1997;277:959-965.
44. Carrington M, Nelson G, Martin M, et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science. 1999;283:1748-1752.
45. Jiang X, Arepally G, Poncz M, McKenzie S. Rapid detection of the Fc gamma RIIA-H/R (131) ligand-binding polymorphism using an allele-specitic restriction enzyme digestion (ASRED). J Immunol Meth. 1996;199:55-59.
46. Hessner M, Curtis B, Endean D, Aster R. Determination of neutrophil antigen gene frequencies in five ethnic groups by polymerase chain reaction with sequence-specific primers. Transfusion. 1996;36:895-899.
47. Masood R, Zheng T, Tupule A, et al. Kaposi's sarcoma-associated herpesvirus infection and multiple myeloma. Science. 1997;278:1970-1973.
48. Davis DA, Humphrey RW, Newcomb FM, et al. Detection of serum antibodies to a Kaposi's sarcoma-associated herpesvirus-specific peptide. J Infect Dis. 1997;175:1071-1079.
49. 2 tests. Biometrics. 1954;10:417-451.
50. Mantel N, Haenszel WJ. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719.
51. Kedes DH, Operskaiski E, Busch M, Kohn R, Flood J, Ganem D. The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med. 1996;2:918-924.
52. Gao SJ, Kingsley L, Li M, et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med. 1996;2: 925-928.
53. Miles SA, Rezai AR, Salazar-Gonzalez JF, et al. AIDS Kaposi's sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci U S A. 1990;87:4068-4072.
54. Nair BC, DeVico AL, Nakamura S, et al. Identification of a major growth factor for AIDS-Kaposi's sarcoma cells as oncostatin M. Science. 1992; 255:1430-1432.
55. Miles SA, Martinez-Maza O, Rezai A, et al. Oncostatin M as a potent mitogen for AIDS-Kaposi's sarcoma-derived cells. Science. 1992;255:1432-1434.
56. Bellamy R. Ruwende C, Corrah T, McAdam KP, Whittle HC, Hill AV. Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. N Engl J Med. 1998;338:640-644.
57. Wirthmueller U, Kurosaki J, Murakami MS, Ravetch JV. Signal transduction by Fc gamma RIII (CD16) is mediated through the gamma chain. J Exp Med. 1992;175:1381-1390.
58. 2+ mobilization and phosphoinositide turnover in human natural killer cells. Role of Ca2+ in Fc gamma R(CD16)-induced transcription and expression of lymphokine genes. J Exp Med. 1989;169:549-567.
59. Jawahar S, Moody C, Chan M, Finberg R, Geha R, Chatila T. Natural killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA(CD16-II). Clin Exp Immunol. 1996;103: 408-413.
60. de Vries E, Koene H. Vossen J, et al. Identification of an unusual Fc gamma receptor IIIa (CD16) on natural killer cells in a patient with recurrent infections. Blood. 1996;88:3022-3027.
61. Chanock SJ, Foster CB. SNPing away at innate immunity. J Clin Invest, 1999;104:369-370.